Replies to post #71685 on Ayala Pharmaceuticals Inc (ADXS)

[jondoeuk]

Nouscom have been working on a number of adenovirus vectors which have a high capacity, potentially encoding for over 100 neoantigens. Some of the NKTR slideshows have said a number of preclinical studies are underway with vaccines and data has been presented http://www.nektar.com/application/files/4015/1041/9944/NKTR-214__2017SITC_Poster-P434.pdf So I wonder if they will conduct a combination trial in the future.